Vitamin B6 metabolism influences the intracellular accumulation of cisplatin

Cell Cycle

Volumn 12, Issue 3, 2013, Pages 417-421

  Galluzzi, Lorenzo ^a,b   Marsili, Sabrina ^c   Vitale, Ilio ^b,d,e   Senovilla, Laura ^b,d,e   Michels, Judith ^b,d,e   Garcia, Pauline ^b,d   Vacchelli, Erika ^b,d,e   Chatelut, Etienne ^c   Castedo, Maria ^b,d,e   Kroemer, Guido ^a,b,d,f,g  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c INSTITUT CLAUDIUS REGAUD   (France)

^d Institut Gustave Roussy   (France)

^e UNIVERSITÉ PARIS SACLAY   (France)

^f HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^g CENTRE DE RECHERCHE DES CORDELIERS   (France)

Author keywords

A549; Apoptosis; N acetyl cysteine; PDXP; Reactive oxygen species; Wilson disease

Indexed keywords

ACETYLCYSTEINE; ATM PROTEIN; CISPLATIN; GLUTATHIONE; PROTEIN P53; PYRIDOXAL KINASE; PYRIDOXINE; SERINE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CELL LEVEL; CELL PROTECTION; CYTOTOXICITY; DNA DAMAGE; DRUG ACCUMULATION; DRUG INHIBITION; DRUG POTENTIATION; DRUG UPTAKE; HUMAN; LUNG NON SMALL CELL CANCER; NONHUMAN; VITAMIN METABOLISM;

MURINAE;

EID: 84875146716     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.23275     Document Type: Article

References (44)

1. Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 2007; 7: 573-84; PMID:17625587; http://dx.doi.org/10.1038/nrc2167
2. Winter C, Albers P. Testicular germ cell tumors: pathogenesis, diagnosis and treatment. Nat Rev Endocrinol 2011; 7: 43-53; PMID:21116298; http://dx.doi.org/10.1038/nrendo.2010.196
3. Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, Kepp O, et al. Molecular mechanisms of cisplatin resistance. Oncogene 2012; 31: 1869-83; PMID:21892204; http://dx.doi.org/10.1038/onc.2011.384
4. Köberle B, Tomicic MT, Usanova S, Kaina B. Cisplatin resistance: preclinical findings and clinical implications. Biochim Biophys Acta 2010; 1806: 172-82; PMID:20647037
5. Carrassa L, Broggini M, Erba E, Damia G. Chk1, but not Chk2, is involved in the cellular response to DNA damaging agents: differential activity in cells expressing or not p53. Cell Cycle 2004; 3: 1177-81; PMID:15326376; http://dx.doi.org/10.4161/cc.3.9.1080
6. Nardella C, Clohessy JG, Alimonti A, Pandolfi PP. Pro-senescence therapy for cancer treatment. Nat Rev Cancer 2011; 11: 503-11; PMID:21701512; http://dx.doi.org/10.1038/nrc3057
7. Kroemer G, Galluzzi L, Brenner C. Mitochondrial membrane permeabilization in cell death. Physiol Rev 2007; 87: 99-163; PMID:17237344; http://dx.doi.org/10.1152/physrev.00013.2006
8. Galluzzi L, Vitale I, Abrams JM, Alnemri ES, Baehrecke EH, Blagosklonny MV, et al. Molecular definitions of cell death subroutines: recommendations of the Nomenclature Committee on Cell Death 2012. Cell Death Differ 2012; 19: 107-20; PMID:21760595; http://dx.doi.org/10.1038/cdd.2011.96
9. Mandic A, Hansson J, Linder S, Shoshan MC. Cisplatin induces endoplasmic reticulum stress and nucleus-independent apoptotic signaling. J Biol Chem 2003; 278: 9100-6; PMID:12509415; http://dx.doi.org/10.1074/jbc.M210284200
10. Berndtsson M, Hägg M, Panaretakis T, Havelka AM, Shoshan MC, Linder S. Acute apoptosis by cisplatin requires induction of reactive oxygen species but is not associated with damage to nuclear DNA. Int J Cancer 2007; 120: 175-80; PMID:17044026; http://dx.doi.org/10.1002/ijc.22132
11. Gonzalez VM, Fuertes MA, Alonso C, Perez JM. Is cisplatin- induced cell death always produced by apoptosis? Mol Pharmacol 2001; 59: 657-63; PMID:11259608
12. Shulga N, Wilson-Smith R, Pastorino JG. Hexokinase II detachment from the mitochondria potentiates cisplatin induced cytotoxicity through a caspase-2 dependent mechanism. Cell Cycle 2009; 8: 3355-64; PMID:19770592; http://dx.doi.org/10.4161/cc.8.20.9853
13. Vandenabeele P, Galluzzi L, Vanden Berghe T, Kroemer G. Molecular mechanisms of necroptosis: an ordered cellular explosion. Nat Rev Mol Cell Biol 2010; 11: 700-14; PMID:20823910; http://dx.doi.org/10.1038/nrm2970
14. Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 2003; 22: 7265-79; PMID:14576837; http://dx.doi.org/10. 1038/sj.onc.1206933
15. Borst P, Rottenberg S, Jonkers j.How do real tumors become resistant to cisplatin? Cell Cycle 2008; 7: 1353-9; PMID:18418074; http://dx.doi.org/10.4161/ cc.7.10.5930
16. Beers MH. Lung carcinoma. In: Porter RS, Jones TV, eds. The Merck manual of diagnosis and therapy. Rahway: Merck & Co., Inc., 2008:2992
17. Jemal A, Thun MJ, Ries LA, Howe HL, Weir HK, Center MM, et al. Annual report to the nation on the status of cancer, 1975-2005, featuring trends in lung cancer, tobacco use, and tobacco control. J Natl Cancer Inst 2008; 100: 1672-94; PMID:19033571; http://dx.doi.org/10.1093/jnci/djn389
18. Panaretakis T. Cisplatin-induced apoptosis and development of resistance are transcriptionally distinct processes. Cell Cycle 2012; 11:3723; PMID:22983001; http://dx.doi.org/10.4161/cc.22114
19. Galluzzi L, Vitale I, Senovilla L, Olaussen KA, Pinna G, Eisenberg T, et al. Prognostic impact of vitamin B6 metabolism in lung cancer. Cell Rep 2012; 2: 257-69; PMID:22854025; http://dx.doi.org/10.1016/j.celrep. 2012.06.017
20. Galluzzi L, Vitale I, Senovilla L, Eisenberg T, Carmona- Gutierrez D, Vacchelli E, et al. Independent transcriptional reprogramming and apoptosis induction by cisplatin. Cell Cycle 2012; 11: 3472-80; PMID:22918244; http://dx.doi.org/10.4161/cc.21789
21. Yao Z, Szabadkai G. Transcriptional profiling of apoptosis: cell death classification moves toward the systems era. Cell Cycle 2012; 11: 3721-2; PMID:22982998; http://dx.doi.org/10.4161/cc.22116
22. Park SA, Choi KS, Bang JH, Huh K, Kim SU. Cisplatin-induced apoptotic cell death in mouse hybrid neurons is blocked by antioxidants through suppression of cisplatin-mediated accumulation of p53 but not of Fas/Fas ligand. J Neurochem 2000; 75: 946-53; PMID:10936175; http://dx.doi.org/10.1046/j.1471- 4159.2000.0750946.x
23. Previati M, Lanzoni I, Corbacella E, Magosso S, Guaran V, Martini A, et al. Cisplatin-induced apoptosis in human promyelocytic leukemia cells. Int J Mol Med 2006; 18: 511-6; PMID:16865238
24. Tajeddine N, Galluzzi L, Kepp O, Hangen E, Morselli E, Senovilla L, et al. Hierarchical involvement of Bak, VDAC1 and Bax in cisplatin-induced cell death. Oncogene 2008; 27: 4221-32; PMID:18362892; http://dx.doi.org/10.1038/onc. 2008.63
25. Lavin MF, Kozlov S. ATM activation and DNA damage response. Cell Cycle 2007; 6: 931-42; PMID:17457059; http://dx.doi.org/10.4161/cc.6.8.4180
26. DeMicco A, Bassing CH. Deciphering the DNA damage histone code. Cell Cycle 2010; 9:3845; PMID:20948284; http://dx.doi.org/10.4161/cc.9.19.13381
27. MacLaine NJ, Hupp TR. How phosphorylation controls p53. Cell Cycle 2011; 10: 916-21; PMID:21350334; http://dx.doi.org/10.4161/cc.10.6.15076
28. Yoshida M, Khokhar AR, Siddik ZH. Biochemical pharmacology of homologous alicyclic mixed amine platinum(II) complexes in sensitive and resistant tumor cell lines. Cancer Res 1994; 54: 3468-73; PMID:8012968
29. Ishida S, McCormick F, Smith-McCune K, Hanahan D. Enhancing tumor-specific uptake of the anticancer drug cisplatin with a copper chelator. Cancer Cell 2010; 17: 574-83; PMID:20541702; http://dx.doi.org/10.1016/j.ccr. 2010.04.011
30. Holzer AK, Howell SB. The internalization and degradation of human copper transporter 1 following cisplatin exposure. Cancer Res 2006; 66: 10944-52; PMID:17108132; http://dx.doi.org/10.1158/0008-5472.CAN-06-1710
31. Ishida S, Lee J, Thiele DJ, Herskowitz I. Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals. Proc Natl Acad Sci USA 2002; 99: 14298-302; PMID:12370430; http://dx.doi.org/10.1073/ pnas.162491399
32. Katano K, Kondo A, Safaei R, Holzer A, Samimi G, Mishima M, et al. Acquisition of resistance to cisplatin is accompanied by changes in the cellular pharmacology of copper. Cancer Res 2002; 62: 6559-65; PMID:12438251
33. Komatsu M, Sumizawa T, Mutoh M, Chen ZS, Terada K, Furukawa T, et al. Copper-transporting P-type adenosine triphosphatase (ATP7B) is associated with cisplatin resistance. Cancer Res 2000; 60: 1312-6; PMID:10728692
34. Zischka H, Lichtmannegger J, Schmitt S, Jägemann N, Schulz S, Wartini D, et al. Liver mitochondrial membrane crosslinking and destruction in a rat model of Wilson disease. J Clin Invest 2011; 121: 1508-18; PMID:21364284; http://dx.doi.org/10.1172/JCI45401
35. Safaei R. Role of copper transporters in the uptake and efflux of platinum containing drugs. Cancer Lett 2006; 234: 34-9; PMID:16297532; http://dx.doi.org/10.1016/j.canlet.2005.07.046
36. Amadasi A, Bertoldi M, Contestabile R, Bettati S, Cellini B, di Salvo ML, et al. Pyridoxal 5'-phosphate enzymes as targets for therapeutic agents. Curr Med Chem 2007; 14: 1291-324; PMID:17504214; http://dx.doi.org/10.2174/ 092986707780597899
37. Johansson M, Relton C, Ueland PM, Vollset SE, Midttun O, Nygård O, et al. Serum B vitamin levels and risk of lung cancer. JAMA 2010; 303: 2377-85; PMID:20551408; http://dx.doi.org/10.1001/jama.2010.808
38. Larsson SC, Orsini N, Wolk A. Vitamin B6 and risk of colorectal cancer: a meta-analysis of prospective studies. JAMA 2010; 303: 1077-83; PMID:20233826; http://dx.doi.org/10.1001/jama.2010.263
39. Harris HR, Cramer DW, Vitonis AF, Depari M, Terry KL. Folate, vitamin B(6), vitamin B(12), methionine and alcohol intake in relation to ovarian cancer risk. Int J Cancer 2011; In press; PMID:21953625
40. de La Motte Rouge T, Galluzzi L, Olaussen KA, Zermati Y, Tasdemir E, Robert T, et al. A novel epidermal growth factor receptor inhibitor promotes apoptosis in non-small cell lung cancer cells resistant to erlotinib. Cancer Res 2007; 67: 6253-62; PMID:17616683; http://dx.doi.org/10.1158/0008-5472.CAN-07- 0538
41. Morselli E, Maiuri MC, Markaki M, Megalou E, Pasparaki A, Palikaras K, et al. Caloric restriction and resveratrol promote longevity through the Sirtuin- 1-dependent induction of autophagy. Cell Death Dis 2010; 1:e10; PMID:21364612; http://dx.doi.org/10.1038/cddis.2009.8
42. Kepp O, Galluzzi L, Lipinski M, Yuan J, Kroemer G. Cell death assays for drug discovery. Nat Rev Drug Discov 2011; 10: 221-37; PMID:21358741; http://dx.doi.org/10.1038/nrd3373
43. Galluzzi L, Morselli E, Vitale I, Kepp O, Senovilla L, Criollo A, et al. miR-181a and miR-630 regulate cisplatin-induced cancer cell death. Cancer Res 2010; 70: 1793-803; PMID:20145152; http://dx.doi.org/10.1158/0008-5472.CAN-09- 3112
44. LeRoy AF, Wehling ML, Sponseller HL, Friauf WS, Solomon RE, Dedrick RL, et al. Analysis of platinum in biological materials by flameless atomic absorption spectrophotometry. Biochem Med 1977; 18: 184-91; PMID:907657; http://dx.doi.org/10.1016/0006-2944(77)90089-8